Polymorph screening of an active material.

Polymorph screening is currently one of the most important tasks for innovators and for generic companies from both pharmaceutical and intellectual property rights aspects. The different polymorphs have different physicochemical properties, such as the crystal polymorph-dependent solubility which influences the bioavailability. A former drug candidate obtained from Sanofi Pharmaceutical Company (Hungary) was investigated to explore its polymorphism, to distinguish the morphologies generated by analytical examinations and to investigate their relative stabilities. An Avantium Crystal 16 automatic laboratory reactor system was used for the polymorph studies and the studies of their dissolution. Eight polymorphs were obtained by crystallization and transformation methods then characterized by XRPD, DSC, and Raman spectroscopy, scanning electron microscopy, and light microscopy. All the morphologies could be stored in solid without any form transformation for a long time (2 years investigated). According to the first relative stability results, Form I, III, IVa, V, VI, VII are unambiguously metastable forms. Form II and IVb have similar thermodynamic stabilities, that were higher than those of the other polymorphs. A special dissolution medium was developed in which the eight polymorphs showed clear differences in the rate of dissolution.

[1]  D. Bugay Characterization of the solid-state: spectroscopic techniques. , 2001, Advanced drug delivery reviews.

[2]  A. Blackburn,et al.  One-solvent polymorph screen of carbamazepine. , 2008, International journal of pharmaceutics.

[3]  Jukka Rantanen,et al.  Solid form screening--a review. , 2009, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[4]  Stephen R Byrn,et al.  Solid-state analysis of the active pharmaceutical ingredient in drug products. , 2003, Drug discovery today.

[5]  R. Tan,et al.  Quantification of polymorphic impurity in an enantiotropic polymorph system using differential scanning calorimetry, X-ray powder diffraction and Raman spectroscopy. , 2011, International journal of pharmaceutics.

[6]  P. Bennema,et al.  The solubility behaviour and thermodynamic relations of the three forms of Venlafaxine free base. , 2009, International journal of pharmaceutics.

[7]  Ivan Marziano,et al.  Towards a PAT-Based Strategy for Crystallization Development , 2005 .

[8]  W. Mccrone,et al.  Pharmaceutical applications of polymorphism. , 1969, Journal of pharmaceutical sciences.

[9]  G A Stephenson,et al.  Characterization of the solid state: quantitative issues. , 2001, Advanced drug delivery reviews.

[10]  Changquan Calvin Sun Solid-state properties and crystallization behavior of PHA-739521 polymorphs. , 2006, International journal of pharmaceutics.

[11]  C. Kontoyannis,et al.  Analysis and stability of polymorphs in tablets: The case of Risperidone. , 2007, Talanta.

[12]  Thomas Rades,et al.  An overview of recent studies on the analysis of pharmaceutical polymorphs. , 2011, Journal of pharmaceutical and biomedical analysis.

[13]  Keith R Horspool,et al.  Development of a targeted polymorph screening approach for a complex polymorphic and highly solvating API. , 2010, Journal of pharmaceutical sciences.

[14]  A. Bansal,et al.  Analytical techniques for quantification of amorphous/crystalline phases in pharmaceutical solids. , 2006, Journal of pharmaceutical sciences.

[15]  Thomas Rades,et al.  Perspectives in the use of spectroscopy to characterise pharmaceutical solids. , 2008, International journal of pharmaceutics.

[16]  Markus Schulz,et al.  Challenges in the development of hydrate phases as active pharmaceutical ingredients--an example. , 2011, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[17]  H. Brittain Polymorphism in Pharmaceutical Solids , 1999 .

[18]  B. Stensland,et al.  Thermodynamic stability and crystal structures for polymorphs and solvates of formoterol fumarate. , 2006, Journal of pharmaceutical sciences.

[19]  Joel Bernstein,et al.  Polymorphism in Molecular Crystals , 2002 .